Incyte

🇺🇸United States
Ownership
-
Employees
2.5K
Market Cap
$12.6B
Website
Introduction

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Clinical Trials
Related News

A Dose-escalation Study in Subjects With Advanced Malignancies

First Posted Date
2010-02-22
Last Posted Date
2017-11-22
Lead Sponsor
Incyte Corporation
Target Recruit Count
45
Registration Number
NCT01072266

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

First Posted Date
2009-08-06
Last Posted Date
2018-03-12
Lead Sponsor
Incyte Corporation
Target Recruit Count
309
Registration Number
NCT00952289

INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs

Phase 2
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: INCB028050
Drug: Placebo
First Posted Date
2009-05-15
Last Posted Date
2018-09-04
Lead Sponsor
Incyte Corporation
Target Recruit Count
127
Registration Number
NCT00902486

Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer

First Posted Date
2009-03-18
Last Posted Date
2018-01-18
Lead Sponsor
Incyte Corporation
Target Recruit Count
68
Registration Number
NCT00864175

A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

First Posted Date
2009-01-12
Last Posted Date
2022-02-08
Lead Sponsor
Incyte Corporation
Target Recruit Count
29
Registration Number
NCT00820950

Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors

Phase 1
Completed
Conditions
Solid Tumors and Hematologic Malignancy
Interventions
Drug: INCB007839
First Posted Date
2009-01-12
Last Posted Date
2018-01-17
Lead Sponsor
Incyte Corporation
Target Recruit Count
41
Registration Number
NCT00820560

A Dose Ranging Study of the Effect of Ruxolitinib Phosphate Cream When Applied to Participants With Plaque Psoriasis

Phase 2
Completed
Conditions
Psoriasis
Interventions
Drug: Ruxolitinib Phosphate
Other: Placebo Cream
First Posted Date
2008-10-23
Last Posted Date
2022-02-09
Lead Sponsor
Incyte Corporation
Target Recruit Count
199
Registration Number
NCT00778700

Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

Phase 2
Terminated
Conditions
Myeloproliferative Neoplasm (MPN)
Interventions
Drug: Ruxolitinib
First Posted Date
2008-07-31
Last Posted Date
2019-10-28
Lead Sponsor
Incyte Corporation
Target Recruit Count
73
Registration Number
NCT00726232

Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes

Phase 2
Terminated
Conditions
Type 2 Diabetes
Interventions
Drug: INCB019602
Drug: Placebo
Drug: Metformin
First Posted Date
2008-06-17
Last Posted Date
2012-10-30
Lead Sponsor
Incyte Corporation
Target Recruit Count
48
Registration Number
NCT00698789

Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics

First Posted Date
2008-06-17
Last Posted Date
2018-02-14
Lead Sponsor
Incyte Corporation
Target Recruit Count
302
Registration Number
NCT00698230
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy